PT-141 Subcutaneous Injection Safely Induces Erection in Erectile Dysfunction Patients
Subcutaneous PT-141 (bremelanotide) safely induced erections in ED patients in a double-blind RCT, with dose-dependent efficacy and pharmacokinetics supporting SC delivery as a practical clinical route.
Quick Facts
What This Study Found
SC PT-141 induced dose-dependent erectile responses in ED patients (double-blind, placebo-controlled) with characterized pharmacokinetics, acceptable safety, and practical SC delivery — advancing toward clinical approval.
Key Numbers
How They Did This
RCT study on pt-141, sexual-health.
Why This Research Matters
Relevant for pt-141, sexual-health, clinical-trials, bioavailability.
The Bigger Picture
Advances peptide therapeutics research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding SC PT-141 induced dose-dependent erectile responses in ED patients (double-blind, placebo-controlled) with characterized pharmacokinetics, acceptable
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2004.
- Original Title:
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
- Published In:
- International journal of impotence research, 16(2), 135-42 (2004)
- Authors:
- Rosen, R C(2), Diamond, L E(4), Earle, D C(3), Shadiack, A M, Molinoff, P B
- Database ID:
- RPEP-00969
Evidence Hierarchy
Frequently Asked Questions
What was studied?
PT-141 Subcutaneous Injection Safely Induces Erection in Erectile Dysfunction Patients
What was found?
Subcutaneous PT-141 (bremelanotide) safely induced erections in ED patients in a double-blind RCT, with dose-dependent efficacy and pharmacokinetics supporting SC delivery as a practical clinical route.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00969APA
Rosen, R C; Diamond, L E; Earle, D C; Shadiack, A M; Molinoff, P B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.. International journal of impotence research, 16(2), 135-42.
MLA
Rosen, R C, et al. "Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.." International journal of impotence research, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Evaluation of the safety, pharmacokinetics and pharmacodynam..." RPEP-00969. Retrieved from https://rethinkpeptides.com/research/rosen-2004-evaluation-of-the-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.